Home > Insider Trading > Filing (0000905718-21-000760)

Filing Details

Accession Number:: 0000905718-21-000760
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-07 08:53:45
Reporting Period:: 2021-06-03

Accepted Time:: 2021-06-07 08:53:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1637715	Reneo Pharmaceuticals Inc.	RPHM	Pharmaceutical Preparations (2834)	472309515

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1784138	Bali Muralidhar	C/O Reneo Pharmaceuticals, Inc. 12230 El Camino Real, Suite 230 San Diego CA 92130		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-03	12,100	$9.25	1,877,375	No	4	P	Indirect	By Abingworth Bioventures 8 LP
Common Stock	Acquisiton	2021-06-04	257	$9.42	1,877,632	No	4	P	Indirect	By Abingworth Bioventures 8 LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Abingworth Bioventures 8 LP
No	4	P	Indirect	By Abingworth Bioventures 8 LP

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.08 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8.
Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.